Efficacy and Safety of Ibrutinib in Patients With CLL and Other Indolent B-cell Lymphomas Who Are Chronic Hepatitis B Virus Carriers or Occult Hepatitis B Virus Carriers

Clinical trial NCT02991638 · UNKNOWN

Trial details

NCT number: NCT02991638
Sponsor: The University of Hong Kong
Status: UNKNOWN
Phase: Phase 3
Study type: INTERVENTIONAL

Chronic Lymphocytic Leukemia Indolent B-cell Lymphomas Chronic Hepatitis B Lymphoma, Small Lymphocytic Mantle-Cell Lymphoma Waldenstrom's Macroglobulinaemia Follicular Lymphoma

Start date: 2016-11-01
Primary completion: 2020-12-01
Enrollment: 62

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.